Topics

Italfarmaco Enters Binding Term Sheet Agreement With Neupharma for an Exclusive Option to Develop and Commercialize Inhaled Teicoplanin

03:00 EDT 1 Aug 2019 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
--Inhaled administration of teicoplanin could provide needed treatment improvement for common cystic fibrosis-related lung infection-- --Term sheet lays groundwork for definitive agreement for Italfarmaco to acquire full global rights-- --Agreement pa...

Other Sources for this Article

Italfarmaco Group
Dr. Antonio Nardi
R&D Portfolio Development Director
+39 02 64432520
a.nardi@italfarmaco.com

Neupharma
Dr.Fabio Borella
President and Co-founder
+39 05 426540
fabio.borella@neupharma.it

Trophic Communications
Gretchen Schweitzer or Joanne Tudorica
+49 (0) 89 2388 7735
schweitzer@trophic.eu or tudorica@trophic.eu

NEXT ARTICLE

More From BioPortfolio on "Italfarmaco Enters Binding Term Sheet Agreement With Neupharma for an Exclusive Option to Develop and Commercialize Inhaled Teicoplanin"

Quick Search

Relevant Topics

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...